Developer docs
API playgroundTry for free, no card

Search company profiles

TEMISIS

Full company profile

uuid02m2b9n

Namestring
TEMISIS
Legal namestring
TEMISIS THERAPEUTICS
Websiteurl
temisis.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVandoeuvre-lès-nancy, France
HQ citystring
Vandoeuvre-lès-nancy
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical biotechnology, small molecule drugs, inflammatory disease therapeutics, psoriasis treatment, drug discovery
Industry2 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAM
Rare Dermatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inflammatory Disease Therapeutics
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Temisis Therapeutics is a pre-clinical biotechnology company developing proprietary small-molecule drug candidates for the treatment of inflammatory diseases, with a primary focus on psoriasis. Its lead program, TEM1657, targets the Th17/23 axis through both topical and oral routes, offering rapid efficacy and a best-in-class safety profile compared to existing corticosteroids and oral treatments such as Apremilast.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Topical application: 4-day healing process as efficient as corticosteroid treatment Dermoval (0.05% Clobetasol)
+2 more records
Product overview1 text field

TEMISIS Therapeutics is a pre-clinical biotechnology company developing novel small-molecule drugs for inflammatory diseases. The company's core product is TEM1657, a proprietary compound targeting the Th17/23 axis for the treatment of psoriasis, available in both topical and oral formulations. The pipeline includes ongoing pre-clinical programs focused on inflammatory conditions with high unmet medical needs.

Product and service1 record
1TEM1657 (lead compound program)
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global biopharma with inflammation/dermatology franchise (Otezla, Enbrel, Tezspire) and active IL-23 development. Broad incumbent with overlapping target biology and commercial reach in psoriasis.

TypeBroad incumbent
Description

Global biopharma leader with Skyrizi (risankizumab, IL-23) and Humira in psoriasis/psoriatic arthritis. Broad incumbent setting the competitive standard Temesis would need to differentiate against.

TypeBroad incumbent
Description

Global pharma with Cosentyx (secukinumab, IL-17A) as a flagship psoriasis franchise. Major incumbent whose biologic franchise defines the Th17-axis competitive landscape Temesis is targeting.

TypeDirect peer
Description

Clinical-stage biotech developing immunology and inflammation therapeutics for serious inflammatory diseases. Comparable pre-clinical-to-clinical inflammation biotech focused on similar unmet needs.

TypeDirect peer
Description

Clinical-stage immunology biotech developing antibody and small-molecule therapeutics for inflammatory and autoimmune diseases, including psoriasis. Directly comparable pre-clinical-to-clinical inflammation biotech with a similar target-class focus.

TypeDirect peer
Description

Clinical-stage small-molecule immunology biotech with pipeline candidates in psoriasis and other inflammatory indications. Directly comparable small-molecule immunology developer with overlapping target mechanisms.

TypeDirect peer
Description

Clinical-stage small-molecule biotech focused on immuno-inflammatory and dermatological diseases. Comparable as a small-molecule-focused dermatology/inflammation developer targeting similar patient populations.

TypeEmerging player
Description

Early-stage UK-based small-molecule drug discovery company developing kinase inhibitors for autoimmune and inflammatory diseases. Comparable emerging small-molecule inflammation developer with similar pre-clinical profile.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Acquired Celgene and now markets Otezla (Apremilast) — the oral psoriasis comparator Temesis benchmarks against. Broad incumbent representing the existing oral standard of care in psoriasis.

10Dice Molecules
TypeDirect peer
Description

Pre-clinical/early-stage small-molecule biotech developing oral IL-17 modulators for inflammatory diseases including psoriasis. Direct mechanistic parallel to Temesis's Th17/23 small-molecule approach (acquired by Eli Lilly in 2023, validating the space).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TEMISIS

Inflammatory Disease Therapeuticstemisis.com

TEMISIS firmographics

Firmographics
Name
TEMISIS
Legal name
TEMISIS THERAPEUTICS
Website
https://temisis.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

TEMISIS industry classification

Industry
Product category
Inflammatory Disease Therapeutics
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAM
Rare Dermatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Preclinical biotechnology
  • Small molecule drugs
  • Inflammatory disease therapeutics
  • Psoriasis treatment
  • Drug discovery

Where TEMISIS is headquartered

Location

Headquarters

HQ city
Vandoeuvre-lès-nancy
HQ country
France
HQ region
Europe

Offices1 record

Markets served

TEMISIS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Marketing channels1 record

TEMISIS product offering

Product offering

Core offering

Temisis Therapeutics is a pre-clinical biotechnology company developing proprietary small-molecule drug candidates for the treatment of inflammatory diseases, with a primary focus on psoriasis. Its lead program, TEM1657, targets the Th17/23 axis through both topical and oral routes, offering rapid efficacy and a best-in-class safety profile compared to existing corticosteroids and oral treatments such as Apremilast.

Product overview

TEMISIS Therapeutics is a pre-clinical biotechnology company developing novel small-molecule drugs for inflammatory diseases. The company's core product is TEM1657, a proprietary compound targeting the Th17/23 axis for the treatment of psoriasis, available in both topical and oral formulations. The pipeline includes ongoing pre-clinical programs focused on inflammatory conditions with high unmet medical needs.

Differentiator

Problem solved

Functional benefit

Products and services

  • TEM1657 (lead compound program)

Quantifiable outcome

  • Topical application: 4-day healing process as efficient as corticosteroid treatment Dermoval (0.05% Clobetasol)
  • +2 more outcomes

Companies that use TEMISIS

Customer profile

Segments1 record

Ideal customer profiles1 record

TEMISIS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

TEMISIS partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

TEMISIS competitors and assessment

Company assessment

Broad incumbents

  • Amgen: Global biopharma with inflammation/dermatology franchise (Otezla, Enbrel, Tezspire) and active IL-23 development. Broad incumbent with overlapping target biology and commercial reach in psoriasis.
  • AbbVie: Global biopharma leader with Skyrizi (risankizumab, IL-23) and Humira in psoriasis/psoriatic arthritis. Broad incumbent setting the competitive standard Temesis would need to differentiate against.
  • Novartis: Global pharma with Cosentyx (secukinumab, IL-17A) as a flagship psoriasis franchise. Major incumbent whose biologic franchise defines the Th17-axis competitive landscape Temesis is targeting.
  • Bristol Myers Squibb: Acquired Celgene and now markets Otezla (Apremilast) — the oral psoriasis comparator Temesis benchmarks against. Broad incumbent representing the existing oral standard of care in psoriasis.

Direct peers

  • Aristea Therapeutics: Clinical-stage biotech developing immunology and inflammation therapeutics for serious inflammatory diseases. Comparable pre-clinical-to-clinical inflammation biotech focused on similar unmet needs.
  • AnaptysBio: Clinical-stage immunology biotech developing antibody and small-molecule therapeutics for inflammatory and autoimmune diseases, including psoriasis. Directly comparable pre-clinical-to-clinical inflammation biotech with a similar target-class focus.
  • Ventyx Biosciences: Clinical-stage small-molecule immunology biotech with pipeline candidates in psoriasis and other inflammatory indications. Directly comparable small-molecule immunology developer with overlapping target mechanisms.
  • Aclaris Therapeutics: Clinical-stage small-molecule biotech focused on immuno-inflammatory and dermatological diseases. Comparable as a small-molecule-focused dermatology/inflammation developer targeting similar patient populations.
  • Dice Molecules: Pre-clinical/early-stage small-molecule biotech developing oral IL-17 modulators for inflammatory diseases including psoriasis. Direct mechanistic parallel to Temesis's Th17/23 small-molecule approach (acquired by Eli Lilly in 2023, validating the space).

Emerging players

  • Sareum Holdings: Early-stage UK-based small-molecule drug discovery company developing kinase inhibitors for autoimmune and inflammatory diseases. Comparable emerging small-molecule inflammation developer with similar pre-clinical profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

TEMISIS social profiles

Digital presence

TEMISIS compliance and trust

Trust signal

Compliance1 record

TEMISIS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TEMISIS leadership team

Management profile

Number of profiles

TEMISIS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TEMISIS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TEMISIS

What does TEMISIS do?

Temisis Therapeutics is a pre-clinical biotechnology company developing proprietary small-molecule drug candidates for the treatment of inflammatory diseases, with a primary focus on psoriasis. Its lead program, TEM1657, targets the Th17/23 axis through both topical and oral routes, offering rapid efficacy and a best-in-class safety profile compared to existing corticosteroids and oral treatments such as Apremilast.

Is TEMISIS a public or private company?

TEMISIS is a private company. It is classified as corporate owned and is currently operating.

When was TEMISIS founded?

TEMISIS was founded in 2017. It employs 1 to 10 people.

Where is TEMISIS based?

TEMISIS is headquartered in Vandoeuvre-lès-nancy, France, in the Europe region.

Who are TEMISIS's main competitors?

Broad incumbents on record are Amgen, AbbVie, Novartis and Bristol Myers Squibb. Direct peers are Aristea Therapeutics, AnaptysBio, Ventyx Biosciences, Aclaris Therapeutics and Dice Molecules. Sareum Holdings is listed as an emerging player.

Does TEMISIS have an API?

No public API is recorded for TEMISIS.

What industry is TEMISIS in?

TEMISIS's product category is Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIAIAM, Rare Dermatology Disorder Therapies. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales